Janux stock plunges after hours following mCRPC trial data
Abbott Laboratories (NYSE:ABT) Senior Vice President Eric Shroff sold 1,586 shares of common stock on November 25, 2025, for approximately $203,042. The shares were sold at prices ranging from $128.02 to $128.06.
Following the transaction, Shroff directly owns 30,384 shares of Abbott Laboratories . The sale was disclosed in a Form 4 filing with the Securities and Exchange Commission.
In other recent news, Abbott Laboratories has announced a definitive agreement to acquire Exact Sciences for $105 per share, valuing the deal at approximately $21 billion. This acquisition is expected to close in the second quarter of 2026 and is projected to enhance Abbott’s Diagnostics segment growth by about 300 basis points. The acquisition aligns with Abbott’s strategy to expand its diagnostics business, which currently accounts for around 20% of its total revenue. Analysts from Benchmark and UBS have reiterated their Buy ratings on Abbott, with UBS raising its price target to $158.00 from $154.00. UBS has emphasized the sustainability of Abbott’s double-digit growth in its MedTech segment, which was highlighted in the company’s third-quarter 2025 earnings report. The firm anticipates this strong performance to continue, suggesting potential upside to 2026 analyst estimates. This development follows reports of Abbott being in discussions to acquire Exact Sciences, a move that could significantly bolster its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.